Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control

Authors:

Abstract
No abstract available
Funding Information
  • Regeneron Pharmaceuticals

This publication has 24 references indexed in Scilit: